Drug intelligence / Profile preview

KP2041

Development stage: Preclinical
Lead developer: K Pharma
Modality: Small Molecules
Administration: Oral

Overview

KP2041 is a small molecule drug candidate being developed by K Pharma, Inc. for the treatment of ferritinopathy (also known as neuroferritinopathy). The program utilizes a drug repositioning strategy, identifying existing compounds that may be effective for this rare genetic neurodegenerative disorder. Ferritinopathy is characterized by the abnormal accumulation of iron and ferritin in the brain, leading to movement disorders and cognitive decline. KP2041 is currently in the preclinical stage, with K Pharma focusing on establishing evaluation systems for compound screening.

Beyond the preview

Go deeper on KP2041.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP2041.

Explore the full profile